Alzheimer's disease
Conditions
Interventions
Precise localization of cognitive impairment in rTMS group:The individual posterior cingulate cortex and the lateral parietal cortex were selected as the effective region and stimulation target, respe
Non-precise localization of cognitive impairment in rTMS group:The target was randomly selected 1 cm away from the strongest functional connectivity within the lateral parietal cortex.
Health control group:None
Sponsors
The Affiliated Hospital of Hangzhou Normal University
Eligibility
Sex/Gender
All
Age
55 Years to 80 Years
Inclusion criteria
Inclusion criteria: Cognitive Impairment Group: (1) age 55-80 years; (2) the diagnosis of mild Cognitive impairment or mild Alzheimer's disease in Sino Longitudinal Study on Cognitive Decline (SILCODE); (3) clinical dementia rating (CDR) score: 0 to 1; (4) mini-mental state examination (MMSE) score:18 to 26; (5) using a stable dose of therapeutic drugs for at least 3 months before TMS; (6) through TMS safety screening, no metal implanted DBS electrode, no epilepsy and other neuropsychiatric disease, no motor system disease; (7) no head injury or serious heart disease was found by MRI screening; (8) has or is not currently participating in other TMS trials; (9) sign the informed consent form. Health control group: (1) age 55-80 years; (2) objective neuropsychological assessment scores within normal range; (3) no cognitive decline or cognitive decline concerns; (4) safety screening by MRI; (5) not recently enrolled in other clinical trials; (6) sign the informed consent form.
Exclusion criteria
Exclusion criteria: Cognitive Impairment Group: (1) obvious adverse reactions; (2) voluntary withdrawal from the trial; (3) those who could not judge the curative effect or whose incomplete data affected the curative effect or safety judgment; (4) all fMRI images were rotated with head-motion amplitude of translation > 3 mm or rotation > 3°. Health control group: (1) voluntary withdrawal from the trial; (2) all fMRI images were rotated with head-motion amplitude of translation > 3 mm or rotation > 3°.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alzheimer's Disease Assessment Scale;Mini-Mental State Examination;Montreal Cognitive Assessment;Magnetic Resonance Imaging;Blood; | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuropsychological Test; | — |
Countries
China
Contacts
Public ContactYufeng Zang
The Affiliated Hospital of Hangzhou Normal University
Outcome results
None listed